Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care - Report - MDSpire
Advertisement
Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care
Clinical Report: Ambulatory Step-Up Dosing of Bispecific Antibodies for RRMM
Overview
This report reviews the operational challenges and clinical considerations of ambulatory step-up dosing of bispecific antibodies for relapsed or refractory multiple myeloma (RRMM). It emphasizes the need for a biologically informed, resource-stratified approach to mitigate early immune-mediated toxicity during outpatient treatment initiation.
Background
Multiple myeloma (MM) is a complex plasma cell malignancy that often becomes relapsed or refractory despite various treatment advances. Bispecific antibodies (BsAbs) have emerged as a significant therapeutic option for RRMM, engaging T cells to target malignant plasma cells. However, the initiation of treatment with these agents poses operational challenges due to the risk of early immune-mediated toxicities, necessitating careful patient selection and monitoring.
Data Highlights
No numerical data provided in the source material.
Key Findings
Ambulatory step-up dosing of BsAbs is a high-acuity care model, not merely a relocation of inpatient administration.
Approved BsAbs differ in their target antigens, dosing schedules, and toxicity profiles, necessitating tailored monitoring protocols.
Patient selection for outpatient dosing should consider clinical stability, immune reserve, and caregiver reliability.
Implementation of outpatient dosing requires robust infrastructure, including clear escalation pathways and immediate access to supportive therapies.
Prospective validation of monitoring criteria and nursing-sensitive outcomes is essential for safe outpatient administration.
Clinical Implications
Healthcare providers must adopt a structured approach to outpatient step-up dosing of BsAbs, ensuring that patient selection and monitoring align with the specific characteristics of each agent. Continuous evaluation and adaptation of protocols will be crucial to enhance safety and efficacy in this high-acuity care setting.
Conclusion
Outpatient step-up dosing of bispecific antibodies represents a promising advancement in the treatment of RRMM, but it requires a comprehensive framework to manage associated risks effectively. Ongoing research and validation of practices will be vital to optimize patient outcomes.
